Top Page
Theralase Technologies
(TLT)
Theralase Technologies (TLT) vs. iShares MSCI Canada ETF (EWC)
Theralase Technologies Business Overview & Revenue Model
Theralase Technologies Earnings Call Summary
Theralase Technologies Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.03M | 1.07M | 1.14M | 780.64K | 929.12K | Gross Profit |
| 554.03K | 562.13K | 628.17K | 309.94K | 269.68K | EBIT |
| 0.00 | -4.59M | -5.20M | -4.52M | -5.59M | EBITDA |
| -3.96M | -4.25M | -4.90M | -4.31M | -5.56M | Net Income Common Stockholders |
| -4.26M | -4.57M | -5.25M | -4.42M | -5.61M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 268.76K | 43.91K | 1.51M | 3.69M | 7.88M | Total Assets |
| 3.25M | 3.28M | 4.16M | 5.94M | 10.02M | Total Debt |
| 293.87K | 386.88K | 473.62K | 35.72K | 92.34K | Net Debt |
| 25.11K | 342.97K | -1.03M | -3.66M | -7.79M | Total Liabilities |
| 1.18M | 1.37M | 1.07M | 874.79K | 857.13K | Stockholders Equity |
| 2.07M | 1.91M | 3.09M | 5.07M | 9.16M |
| Cash Flow | Free Cash Flow | |||
| -3.35M | -4.11M | -5.20M | -4.13M | -4.61M | Operating Cash Flow |
| -3.33M | -4.07M | -5.13M | -4.03M | -4.45M | Investing Cash Flow |
| -19.97K | -37.27K | -70.41K | -100.82K | -164.58K | Financing Cash Flow |
| 3.57M | 2.65M | 3.02M | -57.37K | -57.56K |
Theralase Technologies Technical Analysis
Theralase Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | C$24.98M | ― | -23.87% | ― | 18.97% | 17.57% | |
62 Neutral | $11.93B | 10.60 | -7.51% | 3.00% | 7.40% | -8.09% | |
51 Neutral | C$6.82M | ― | -203.19% | ― | 69.93% | 20.54% | |
50 Neutral | C$21.98M | ― | -163.62% | ― | 113.85% | 11.38% | |
45 Neutral | C$46.40M | ― | -291.48% | ― | -8.63% | 7.04% | |
44 Neutral | C$20.42M | ― | 207.08% | ― | 280.56% | -7.28% | |
40 Underperform | $74.84M | ― | -79.91% | ― | ― | -44.50% |
Theralase Technologies Corporate Events
Theralase Technologies Inc. has announced its upcoming Annual General and Special Meeting (AGSM) scheduled for June 11, 2025. The meeting will be held at their Toronto head office and will include a virtual presentation for shareholders unable to attend in person. This presentation will outline the company’s strategic objectives for 2025 and 2026 and provide a platform for shareholder engagement through a question and answer session. This initiative reflects Theralase’s commitment to transparency and shareholder involvement, potentially strengthening its industry position and stakeholder relations.
Theralase Technologies reported a significant decline in revenue for the first quarter of 2025, with a 48% year-over-year decrease to $91,190. Despite increased research and development expenses to support ongoing studies, the company faced a net loss of $1,471,250. Operationally, Theralase completed two non-brokered private placements, raising funds to support its research programs. The company is advancing its Herpes Simplex Virus treatment program and has made progress in its Phase II bladder cancer study, with promising interim results showing a 62% complete response rate among patients.
Theralase Technologies Inc. is set to present groundbreaking research at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, showcasing promising preclinical results of their drug Rutherrin®. This ruthenium-based small molecule, when activated by radiation, demonstrates a dual-action strategy against cancer by inducing immediate cytotoxicity and stimulating a durable immune response. The study highlights Rutherrin®’s potential to enhance radiation therapy effectiveness, offering a major advancement in oncologic treatment. Theralase plans to complete GLP toxicology studies in 2025, aiming to launch clinical studies in early 2026 targeting aggressive cancers such as GBM, lung, pancreatic, lymphoma, and colorectal cancers.
Theralase Technologies has announced promising preclinical results showing that its radiation-activated drug, Rutherrin, is significantly more effective than traditional radiation therapy in destroying cancer cells. The research, which will be presented at the ASTRO 2025 Annual Meeting, highlights Rutherrin’s ability to target tumors selectively, penetrate the blood-brain barrier, and activate a sustained immune response, potentially improving patient outcomes and overcoming treatment resistance.
Theralase Technologies has made significant progress in its Study II for BCG-unresponsive non-muscle invasive bladder cancer, with 91% of patient enrollment completed. The interim clinical data shows promising results, with a strong complete response rate and no serious adverse events reported. The company plans to complete enrollment by summer 2025 and submit a New Drug Application by 4Q2026. Additionally, Theralase is exploring international partnerships for the commercialization of its Ruvidar® treatment and has completed pre-clinical research for its use in treating glioblastoma multiforme brain cancer.
Theralase Technologies Inc. recently presented interim clinical data at the Canadian Bladder Cancer Forum and the American Urological Association Annual Meeting, showcasing the safety and efficacy of their treatment for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. The data revealed that 62.5% of patients achieved a complete response, with some maintaining this response for over three years, highlighting the potential impact of Theralase’s light-activated small molecule treatment on cancer therapy.
Theralase Technologies has announced a significant discovery in its cancer treatment research, revealing that its lead drug, Ruvidar™, effectively inhibits DeUbiquitinating Enzymes (DUBs), which are linked to cancer and neurodegenerative diseases. This discovery positions Ruvidar™ as a promising candidate for overcoming drug resistance in cancer treatments, potentially expanding its application to neurodegenerative diseases and infectious diseases, marking a milestone in Theralase’s small molecule program.
Theralase Technologies Inc. has successfully closed a non-brokered private placement, raising $CAN 419,124 through the issuance of 1,995,829 units. The proceeds will be used to advance their Phase II clinical study on Non-Muscle Invasive Bladder Cancer, research on Herpes Simplex Virus treatment, and development of Rutherrin® for various solid-core tumors. This financing move is expected to bolster the company’s ongoing research and development efforts, potentially enhancing its position in the pharmaceutical industry.
Theralase Technologies has announced that its product, Ruvidar, has demonstrated higher efficacy in treating Herpes Simplex Virus, Type 1 (HSV-1) compared to FDA-approved treatments Acyclovir and Abreva in a preclinical animal model. The research showed that Ruvidar, applied once daily, was able to completely heal HSV-1 lesions, unlike the other treatments which required more frequent applications and higher doses. This promising result suggests a potential advancement in HSV-1 treatment, with implications for further clinical studies and possible market introduction.
Theralase Technologies has announced a significant milestone in its Phase Ib clinical study for Non-Muscle Invasive Bladder Cancer (NMIBC). A patient treated with their light-activated small molecule Ruvidar demonstrated a complete response lasting over seven years, highlighting the potential of Ruvidar in treating BCG-unresponsive NMIBC Carcinoma In-Situ. This development underscores the effectiveness of Theralase’s approach in addressing challenging cancer types and positions the company for further clinical advancements and regulatory submissions.
Theralase Technologies has released its audited consolidated financial statements for the year ending December 31, 2024. The company will hold a conference call on March 19, 2025, to discuss the financial and operational results, providing stakeholders with insights into its performance and future prospects.